



MS in Turkey




WHAT IS MS?

Multiple sclerosis (MS) is a complex neurodegenerative disease affecting approximately 70,000 of the 88.3 million¹ people in Turkey.

Each person will experience this unpredictable disease differently, but common symptoms often include pain, fatigue, reduced mobility and cognitive dysfunction.

There is currently no cure for MS; however, optimal treatment and support have a significant effect on disease progression and quality of life for people with MS.



PAIN



FATIGUE



REDUCED MOBILITY



COGNITIVE DYSFUNCTION


COUNTRY CONTEXT



Healthcare in Turkey is organised and delivered by the Ministry of Health through a range of public and private providers, with financing provided by the Social Security Institution.² Turkey provides universal healthcare through a general health insurance scheme.



COUNTRY RANKING



HOW DOES TURKEY SCORE COMPARED TO OTHER COUNTRIES?

(All countries are evaluated on a 0-100 scale)



WHAT DID THE BAROMETER FIND?

Turkey has recently increased the number of treatment and rehabilitation options available to people with MS. There has also been an increase in the number of MS specialists. However, there are still gaps that need to be addressed:




There are delays of 9–18 months to approving new disease-modifying drugs (DMDS) for use and reimbursement.



There are just **3,000** practising neurologists in the country and **only 150** MS specialist neurologists – one for every 467 people with MS.



Under 25% of people with MS with higher disabilities have access to occupational or cognitive rehabilitation.



POLICY RECOMMENDATIONS

Develop a national neurological disease plan that includes a comprehensive approach to MS, with an adequate budget for implementation.



Increase the number of neurologists, including MS specialist neurologists, and reduce delays to national approval of MS therapies to ensure that every person with MS has timely access to specialist care and appropriate treatments.

Expand the number of rehabilitation centres and availability of unlimited therapy without restrictions.



More information can be found at www.emsp.org or contact

iaktan@turkiyemsernegi.org

EMSP would like to thank the sponsors which have financially supported this project including Almirall, Biogen, Bristol Myers Squibb, MedDay, Merck, Mylan, Novartis, Roche, and Sanofi Genzyme. EMSP retains editorial control of the Barometer.

